本页面由Tiger Trade Technology Pte. Ltd.提供服务

Can-Fite Biopharma Ltd

1.95
+0.05002.63%
盘后:1.950.00000.00%19:34 EDT
成交量:2.44万
成交额:4.75万
市值:591.14万
市盈率:0.00
高:2.02
开:1.91
低:1.91
收:1.90
52周最高:12.30
52周最低:1.90
股本:303.15万
流通股本:214.25万
量比:0.61
换手率:1.14%
股息:- -
股息率:- -
每股收益(TTM):-977.1003
每股收益(LYR):-1,791.0249
净资产收益率:-211.37%
总资产收益率:-77.12%
市净率:1.22
市盈率(LYR):0.00

数据加载中...

2026/04/01

SEC问询函

Form CORRESP - Correspondence
2026/03/26

年度报告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2025/07/25

[修订]招股说明书

Form F-1/A - Registration statement for certain foreign private issuers: [Amend]
2025/07/25

SEC问询函

Form CORRESP - Correspondence
2025/07/25

SEC问询函

Form CORRESP - Correspondence
2025/07/23

招股说明书

Form F-1 - Registration statement for certain foreign private issuers
2025/07/17

SEC问询函

Form CORRESP - Correspondence
2025/04/14

年度报告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2024/11/14

超过5%披露

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2024/09/06

SEC问询函

Form CORRESP - Correspondence
2024/04/05

员工持股计划

Form S-8 - Securities to be offered to employees in employee benefit plans
2024/03/28

年度报告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2024/02/14

超过5%披露

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
2024/01/03

SEC问询函

Form CORRESP - Correspondence
2023/09/11

SEC问询函

Form CORRESP - Correspondence
2023/04/21

员工持股计划

S-8 - Securities to be offered to employees in employee benefit plans
2023/03/30

年度报告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2023/02/10

[修订]招股说明书

F-1/A [Amend] - Registration statement for certain foreign private issuers
2023/02/08

SEC问询函

CORRESP [Cover] - Correspondence
2023/01/31

招股说明书

F-1 - Registration statement for certain foreign private issuers